Overview
Inotiv
Inotiv is a leading contract research organization (CRO) specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries, and sells analytical instruments to the pharmaceutical development and contract research industries. The company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all
...
Read More while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. The vast majority of its total revenue accounts in the US. The company was founded as Bioanalytical Systems, Inc. in 1974 by Purdue University chemistry professor Peter Kissinger.
Read Less
Read More while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. The vast majority of its total revenue accounts in the US. The company was founded as Bioanalytical Systems, Inc. in 1974 by Purdue University chemistry professor Peter Kissinger.
Read Less
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Commercial physical research
,
Medical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Modelled
?
Actual
$490.74 million
Actual
-14.27%
$781
SEP
?
?
NASDAQ:NOTV
Contacts
Get in Touch with 6 Principals* and 547 Contacts
-
Robert W Leasure JuniorPresident and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of September 30, 2024 (12 month period) in USD
Annual Revenue 2024
$490.74 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$7 | $28 | -$5 |
| Net Investing Cash | -$17 | -$29 | -$334 |
| Net Financing Cash | $10 | $16 | $203 |
| Net Change in Cash | -$14 | $15 | -$136 |
| Cash at Beginning of Period | $35 | $19 | $157 |
| Cash at End of Period | $21 | $35 | $19 |
| Capital Expenditure | -$22 | -$28 | -$36 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $21 | $35 | $19 |
| Accounts Receivable | $66 | $78 | $89 |
| Inventories | $18 | $56 | $71 |
| Other Current Assets | $58 | $45 | $54 |
| Asset Summary | |||
| Total Current Assets | $163 | $214 | $233 |
| Tangible Fixed Assets | $237 | $230 | $219 |
| Intangible Assets | $274 | $308 | $346 |
| Total Assets | $781 | $857 | $963 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $34 | $33 | $29 |
| Short-Term Debt | $4 | $8 | $23 |
| Other Current Liabilities | $82 | $92 | $112 |
| Liability Summary | |||
| Total Current Liabilities | $119 | $132 | $164 |
| Long-Term Debt | $390 | $370 | $331 |
| Other Long-Term Liabilities | $35 | $6 | $6 |
| Total Liabilities | $611 | $588 | $603 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $6 | $6 | $6 |
| Retained Earnings | -$562 | -$453 | -$348 |
| Equity Summary | |||
| Total Equity | $171 | $269 | $360 |
| Shares Outstanding | 26,015,129 | 25,777,169 | 25,598,289 |